Although we identified very few genes that overlap between studies, our review suggests that some of the genes acting in the PI3K pathway, such as PRKACA[97], might play an important role in developing resistance to anti-HER2 agents in breast cancer patients. This evidence concerns the gene ERBB2 and breast carcinoma.